HC Wainwright Has Bullish Estimate for AXSM FY2026 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at HC Wainwright boosted their FY2026 earnings per share estimates for Axsome Therapeutics in a research report issued on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $3.91 per share for the year, up from their previous forecast of $3.72. HC Wainwright has a “Buy” rating and a $260.00 price objective on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2026 earnings at $2.06 EPS.

Several other analysts have also weighed in on the stock. Morgan Stanley lowered shares of Axsome Therapeutics from an “overweight” rating to a “reduce” rating in a report on Thursday, January 8th. Oppenheimer reaffirmed an “outperform” rating and set a $220.00 price target on shares of Axsome Therapeutics in a report on Wednesday, December 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Wednesday, October 8th. Guggenheim restated a “buy” rating and set a $205.00 target price on shares of Axsome Therapeutics in a report on Friday, January 2nd. Finally, B. Riley initiated coverage on Axsome Therapeutics in a report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 price target for the company. Nineteen analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $202.00.

Axsome Therapeutics Trading Up 4.1%

Shares of AXSM stock opened at $184.50 on Wednesday. The company has a market capitalization of $9.30 billion, a P/E ratio of -39.51, a P/E/G ratio of 9.74 and a beta of 0.44. Axsome Therapeutics has a 12-month low of $86.99 and a 12-month high of $185.98. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. The firm has a 50-day moving average price of $156.51 and a 200 day moving average price of $131.77.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The firm had revenue of $170.99 million during the quarter, compared to analyst estimates of $162.96 million. The business’s revenue was up 63.2% on a year-over-year basis.

Insider Transactions at Axsome Therapeutics

In other news, Director Mark E. Saad sold 37,577 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $165.18, for a total value of $6,206,968.86. Following the transaction, the director owned 10,002 shares of the company’s stock, valued at approximately $1,652,130.36. This trade represents a 78.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Herriot Tabuteau sold 91,705 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $132.34, for a total transaction of $12,136,239.70. Following the completion of the transaction, the chief executive officer owned 7,229 shares in the company, valued at $956,685.86. This represents a 92.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 420,903 shares of company stock worth $63,552,838. Corporate insiders own 22.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AXSM. Allworth Financial LP raised its holdings in shares of Axsome Therapeutics by 6.6% during the 3rd quarter. Allworth Financial LP now owns 1,442 shares of the company’s stock worth $175,000 after buying an additional 89 shares in the last quarter. Moors & Cabot Inc. raised its stake in Axsome Therapeutics by 4.5% during the 2nd quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock worth $243,000 after buying an additional 100 shares during the period. Meridian Wealth Management LLC grew its stake in Axsome Therapeutics by 0.5% in the third quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock valued at $2,687,000 after acquiring an additional 103 shares during the period. GAMMA Investing LLC increased its holdings in shares of Axsome Therapeutics by 65.4% during the fourth quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock valued at $49,000 after acquiring an additional 106 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Axsome Therapeutics by 1.1% during the second quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock worth $1,032,000 after purchasing an additional 107 shares during the period. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.